“The Globalization of Drug Patenting and Competition:
New Evidence from India,” with Bhaven Sampat and Ken Shadlen.
“Estimating the Effects on Mortality Rates of Cancer
Drug Innovation,” with Pierre Dubois
“Experts and Conflicts of Interest: Evidence from FDA
Advisory Committees,” with Fanny Camara.
“Intellectual Property Rights and Access to
Innovation: Evidence from TRIPS,” with Yi Qian.
“Incentives for Pharmaceutical Innovation: What’s
Working, What’s Lacking” (2022), International Journal of Industrial
Organization, 84(September).
“Economic
Issues in Assessing Potential and Nascent Competition” (with Andrew
Elzinga, Nikhil Gupta and Vivek Mani), CPI Antitrust Chronicle, February 2022.
“Intersection
of Intellectual Property and Competition Policy in Recent Cases” (with
Vivek Mani and Sinan Corus), forward to Concurrences e-Competitions Special Issue
on Intellectual Property, 9 May 2022.
“COVID-19
and clinical trials” (2022) in Carsten
Fink, Yann Ménière, and Andrew Toole, eds., Resilience
and Ingenuity: Global Innovation Responses to Covid-19, CEPR e-Book.
“The Alignment of Innovation
Policy and Social Welfare: Evidence from Pharmaceuticals” Innovation
Policy and the Economy Volume
20 (University of Chicago Press, 2020), pp. 95-123.
“The More We Die,
The More We Sell? A Simple Test of the Home-Market Effect” (2019), with
Arnaud Costinot, Dave Donaldson, and Heidi Williams, Quarterly Journal of Economics,
134(2):843-894.
“The Single Market in
Pharmaceuticals” (2019), Review of
Industrial Organization, 55(1):111-135.
“Trade in IP-Intensive Goods” (2022), with Mercedes
Delgado, in Antony Taubman and
Jayashree Watal, editors, Trade in Knowledge (Cambridge University Press).
“Are Important Innovations Rewarded? Evidence
from Pharmaceutical Markets” (2018), Review of Industrial Organization,
53(1):211-234.
“Strategic Interaction among Governments in the
Provision of a Global Public Good” (2017), with David Ridley and Su
Zhang, Journal of Public Economics, 156: 185-199.
“Is American Health Care
Uniquely Inefficient? Evidence from Prescription Drugs” (2017), with Heidi
L. Williams, American Economic Review
Papers & Proceedings, 107(5):486-490.
“Competition
Law, Intellectual Property, and the Pharmaceutical Sector” (2016), Antitrust Law Journal 81(1).
“Competition and the
Efficiency of Markets for Technology” (2015), with Marie-Laure Allain and Emeric Henry, Management
Science 62(4), 1000 - 1019.
“Intellectual
Property Protection and the Geography of Trade” (2013), with Mercedes
Delgado and Anita McGahan, Journal of
Industrial Economics 61(3): 733-762.
“Alliances, Mergers and Acquisitions,” with Henry
Grabowski, in Anthony J. Culyer, editor, Elsevier
Encyclopedia of Health Economics (Elsevier, 2013).
“Investments
in Pharmaceuticals Before and After TRIPS” (2012), with Anita McGahan, Review of Economics and Statistics,
94(4): 1157-1172.
“Markets
for Pharmaceutical Products,” with Fiona Scott Morton, Handbook of
Health Economics Vol. 2 (edited by Mark Pauly, Thomas McGuire and Pedro
Pita Barros), 2012.
“Mergers,
Acquisitions, and Alliances” with Henry Grabowski, Chapter 18 in Handbook
of the Economics of the BioPharmaceutical Industry (edited
by Patricia Danzon and Sean Nicholson), 2012.
“Evolving
Brand-Name And Generic Drug Competition May Warrant A Revision Of The
Hatch-Waxman Act,'' with Henry Grabowski, Richard Mortimer, Genia Long and Noam
Kirson, November 2011, Health Affairs 30:2157-2166.
“Assessing
the population health impact of market interventions to improve access to
antiretroviral treatment,” with Till Barnighausen,
Joshua Salomon and Brenda Waning, September 2011, Health Policy and Planning, doi: 10.1093/heapol/czr058.
“Strategic Responses
to Parallel Trade," 2011, B.E.
Journal of Economic Analysis and Policy: Advances, Vol. 11
: Iss. 2 (Advances), Article 2.
“Intervening in
global markets to improve access to HIV/AIDS treatment: an analysis of
international policies and the dynamics of global antiretroviral medicines
markets" (with Brenda Waning, Ellen Diedrichsen,
Lyne Soucy, Jenny Hochstadt, Till Barnighausen
and Suerie Moon), Globalization
and Health 2010, 6:9.
“Parallel Trade in
Pharmaceuticals: Firm Responses and Competition Policy," Chapter 13 in
International Antitrust Law & Policy: Fordham Competition Law 2009,
edited by Barry Hawk (Juris Publishing, New York, 2009).
“Comparative advantages of push
and pull incentives for technology development: lessons for neglected
diseases" with Cheri Grace, in Global
Forum Update on Research for Health Volume 6, 2009.
“Does Re-importation Reduce
Price Differences for Prescription Drugs? Lessons from the European
Union," with Jennifer Allsbrook and Kevin
Schulman, Health Services Research
August 2008, 43(4), 1308-1324.
“Mergers and
Alliances in Pharmaceuticals: Effects on Innovation and R&D
Productivity," with Henry Grabowski, in The Economics of Corporate
Governance and Mergers, edited by Klaus Peter Gugler
and B. Burcin Yurtoglu
(Cheltenham, UK: Edward Elgar Publishing, 2008).
“Would Greater Price
Transparency and Uniformity Benefit Poor Patients?" with David Ridley,
Health Affairs Sept/Oct 2007, 26(5),
1384-1391.
“Generic
Competition and Market Exclusivity Periods in Pharmaceuticals," with
Henry Grabowski, Managerial and Decision
Economics June-August 2007, 28(4-5), 491-502.
"Pharmaceutical Price
Controls and Entry Strategies," Review of Economics and Statistics February 2007, 89(1), 88-99
"The Role of Firm
Characteristics in Pharmaceutical Product Launches," RAND Journal of Economics Autumn 2006,
37(3), 602-618.
“Objective and Self-Reported Work Performance
Measures: A Comparative Analysis," with Glenn Pransky,
Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan
Tortorice (2006), International
Journal of Productivity & Performance Management 55(5), 390-399.
"Surviving the Gales of
Creative Destruction: The Determinants of Product Turnover,"
with John M. de Figueiredo (2006), Strategic Management Journal 27(3),
241-264.
"Public & Private Spillovers,
Location, and the Productivity of Pharmaceutical Research," with Jeff Furman, Iain Cockburn, and Rebecca
Henderson, Annales d'Economie
et Statistique 2005, 79/80, 165-188.
“Product Launch Decisions by Dominant and Fringe
Firms," with John M. de Figueiredo, Best Paper Proceedings of the Academy of
Management, 2005.
"Does Locale Affect
R&D Productivity? The Case of
Pharmaceuticals," Federal
Reserve Bank of San Francisco Economic Letter, Nov. 13, 2004.
"The Long Shadow of
Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?"
with Ernst R. Berndt and Davina Ling, Scanner Data and Price Indexes,
edited by Robert Feenstra and Matthew Shapiro
(Chicago: University of Chicago Press, 2003), 229-267.
"Deregulating
Direct-to-consumer Marketing of Prescription Drugs: Effects on Prescription and
Over-the-counter Sales" with Ernst R. Berndt and Davina Ling
(2002), Journal of Law and Economics
44 (3), 691-723.
“Did U.S. Bank Supervisors Get Tougher During the
Credit Crunch? Did it Matter to Bank Lending?" with Allen N. Berger and
Joseph M. Scalise in Prudential Supervision: What Works and What Doesn't,
edited by Frederic Mishkin (Chicago: University of Chicago Press, 2001).